Metabolic Syndrome and psoriatic arthritis: considerations for the clinician.
Francesco CasoMaria Sole ChimentiLuca NavariniRoberto CaporaliRosario PelusoNicolò GirolimettoAntonio Del PuenteRoberto GiacomelliRaffaele ScarpaLuisa CostaPublished in: Expert review of clinical immunology (2020)
Introduction: Metabolic Syndrome (MetS) is strictly interconnected with systemic inflammation, and increased evidence has described a close link between this condition and Psoriatic Arthritis (PsA).Areas covered: This review summarizes main studies exploring clinical aspects and prevalence of MetS in PsA cohorts. Further, there is accumulating evidence showing shared inflammatory pathways between MetS, its components, and PsA.Expert opinion: The high prevalence of MetS in PsA highlights the need for screening, evaluation, and close monitoring of MetS and its components (namely, diabetes mellitus, obesity, hypertension, and dyslipidemia) in psoriatic patients.Further studies should focus on the pathogenetic link between MetS and PsA. More studies are required to identify appropriate algorithms for the assessment and management of MetS in PsA patients.
Keyphrases
- prostate cancer
- metabolic syndrome
- end stage renal disease
- radical prostatectomy
- ejection fraction
- newly diagnosed
- chronic kidney disease
- insulin resistance
- machine learning
- peritoneal dialysis
- oxidative stress
- physical activity
- risk factors
- deep learning
- body mass index
- cardiovascular risk factors
- systemic lupus erythematosus